But in subsequent discussions, the agency had relented and agreed to begin a review, the company said on Wednesday. As part of the revised approach, Moderna said that it had agreed to split up its application for the flu vaccine based on age. It plans to seek standard approval for people 50 to 64 years old, and accelerated approval for those 65 and older. The company also said it had agreed to conduct an additional study among those 65 and older once the vaccine reached the market.